Novo Nordisk A/S
NVO
$78.11
-$0.84-1.06%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 28.79% | 22.51% | 23.78% | 23.75% | 43.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.79% | 22.51% | 23.78% | 23.75% | 43.94% |
| Cost of Revenue | 24.80% | 17.47% | 29.15% | 22.47% | 21.71% |
| Gross Profit | 29.46% | 23.51% | 22.87% | 23.98% | 48.55% |
| SG&A Expenses | 7.77% | 18.95% | 3.09% | 8.03% | 29.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -137.08% | 203.99% | -2,766.30% | 1,839.38% | 25.00% |
| Total Operating Expenses | 15.42% | 18.89% | 18.28% | 19.38% | 28.48% |
| Operating Income | 45.90% | 26.81% | 30.78% | 28.69% | 70.13% |
| Income Before Tax | 27.44% | 23.63% | 3.14% | 30.39% | 77.91% |
| Income Tax Expenses | 28.22% | 27.97% | 8.08% | 33.65% | 118.26% |
| Earnings from Continuing Operations | 27.24% | 22.55% | 1.92% | 29.58% | 69.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.24% | 22.55% | 1.92% | 29.58% | 69.83% |
| EBIT | 45.90% | 26.81% | 30.78% | 28.69% | 70.13% |
| EBITDA | 44.43% | 23.30% | 31.77% | 31.43% | 66.34% |
| EPS Basic | 27.77% | 23.22% | 2.66% | 30.73% | 71.46% |
| Normalized Basic EPS | 38.60% | 24.33% | 27.29% | 31.55% | 78.45% |
| EPS Diluted | 27.85% | 23.50% | 2.65% | 30.75% | 71.38% |
| Normalized Diluted EPS | 38.69% | 24.41% | 27.40% | 31.62% | 78.53% |
| Average Basic Shares Outstanding | -0.41% | -0.55% | -0.73% | -0.88% | -0.96% |
| Average Diluted Shares Outstanding | -0.49% | -0.63% | -0.83% | -0.95% | -1.00% |
| Dividend Per Share | 22.20% | -- | 15.22% | -- | 65.07% |
| Payout Ratio | -- | -0.04% | -- | 0.21% | -- |
